



Circulating Tumor Cells (CTCs): Current and Emerging Utility in Cancer

Guest Editors:

Dr. Michele Zanoni

Istituto Romagnolo per lo Studio
dei Tumori "Dino Amadori"-IRST
S.r.l., 47014 Meldola, Italy

Dr. Tania Rossi

IRCCS Istituto Scientifico per la
cura dei Tumori "Dino Amadori"
IRST, Meldola, Italy

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editors

Dear Colleagues,

CTCs are a rare population of cells shed in the bloodstream by primary epithelial tumors that move towards distant organs to generate metastasis. In a translational context, CTC enumeration, detection and characterization (at both phenotypic and molecular levels) were proven to have a clinical significance, especially in early epithelial cancer detection and prognosis prediction. Given their availability in the peripheral blood, CTC analysis allows also for therapy response and minimal residual disease (MRD) monitoring. However, the discovery of new CTC markers in different cancer types is a critical step in developing new methods for CTC detection and improving recovery. Furthermore, thanks to CTCs in vitro culturing it is possible to increase their numbers, simplifying the analysis of their biological and molecular features and allowing for a deeper comprehension of the nature of tumors.

Topics of this Special Issue can include but are not limited to:

- CTC biology;
- Tumor progression;
- Minimal residual disease (MRD);
- Therapy response monitoring;
- Metastatic organotropism;
- New methods for CTC detection and characterization;
- CTC-derived in vitro models.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI